Cns Pharmaceuticals Inc (CNSP)

$3.13 -0.08 (-2.49%)
Market Cap 1.99M
Revenue (ttm) 0.00
Net Income (ttm) -14.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,500
Avg Vol 43,534
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 6%
Beta 2.70
Analysts Strong Sell
Price Target $20.00

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 800 946 9185
Address:
2100 West Loop South, Suite 900, Houston, United States
Eddie5150
Eddie5150 Feb. 24 at 4:34 PM
$CNSP
0 · Reply
youbi336
youbi336 Feb. 24 at 12:12 PM
$CNSP the new CEO is busy licking his own ass while the stock price is bleeding. They don't seem interested in protecting it and would rather start from a 5th reverse split apparently.
0 · Reply
LimitScopeX_898
LimitScopeX_898 Feb. 24 at 11:40 AM
$CNSP biotech thin float tight range if buyers push resistance breakout
0 · Reply
TheMorningStew
TheMorningStew Feb. 24 at 3:22 AM
$CNSP skipping around at yearly low - patience for good PR can do 2x gained (619k float)
0 · Reply
kAPPA_92Flow
kAPPA_92Flow Feb. 23 at 2:52 PM
$CNSP Energy optimization in cold storage is not marginal. On a ~$3.2M annual bill, a 15–20% peak demand reduction can generate approximately $250K in demand savings. Additional $80K–$120K from load shifting strengthens margins while maintaining a battery reserve for outage events
0 · Reply
_Meowzilla1
_Meowzilla1 Feb. 23 at 12:30 PM
$GOVX $CNSP $CGTL $PLAG \|\
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 8:58 PM
$CNSP https://youtu.be/nCPt9XhiRxk
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 5:33 PM
$CNSP https://youtu.be/VcWJkTGHJVM
0 · Reply
UCF_16
UCF_16 Feb. 21 at 12:48 PM
$CNSP
0 · Reply
UCF_16
UCF_16 Feb. 20 at 1:49 PM
$CNSP
0 · Reply
Latest News on CNSP
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

Feb 17, 2026, 8:25 AM EST - 7 days ago

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

CNS Pharmaceuticals Issues Letter to Shareholders

Jan 27, 2026, 9:00 AM EST - 4 weeks ago

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals Announces CEO Transition

Dec 17, 2025, 7:00 AM EST - 2 months ago

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 17, 2025, 1:17 PM EST - 3 months ago

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:35 AM EST - 3 months ago

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

Nov 10, 2025, 8:45 AM EST - 3 months ago

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 6 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 8:05 AM EDT - 6 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 6 months ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 7 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 18, 2025, 8:00 AM EDT - 7 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jul 9, 2025, 9:32 AM EDT - 8 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 24, 2025, 9:15 AM EDT - 8 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

Jun 5, 2025, 8:05 AM EDT - 9 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:05 AM EDT - 10 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 9:35 AM EDT - 10 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025, 7:00 AM EDT - 10 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Apr 1, 2025, 8:05 AM EDT - 11 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 12:05 PM EDT - 1 year ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 26, 2025, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 20, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 18, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 10, 2025, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Dec 5, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 25, 2024, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 18, 2024, 8:55 AM EST - 1 year ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 4, 2024, 9:15 AM EST - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 23, 2024, 9:00 AM EDT - 2 years ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 22, 2024, 10:15 AM EDT - 2 years ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 5:00 PM EDT - 2 years ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Eddie5150
Eddie5150 Feb. 24 at 4:34 PM
$CNSP
0 · Reply
youbi336
youbi336 Feb. 24 at 12:12 PM
$CNSP the new CEO is busy licking his own ass while the stock price is bleeding. They don't seem interested in protecting it and would rather start from a 5th reverse split apparently.
0 · Reply
LimitScopeX_898
LimitScopeX_898 Feb. 24 at 11:40 AM
$CNSP biotech thin float tight range if buyers push resistance breakout
0 · Reply
TheMorningStew
TheMorningStew Feb. 24 at 3:22 AM
$CNSP skipping around at yearly low - patience for good PR can do 2x gained (619k float)
0 · Reply
kAPPA_92Flow
kAPPA_92Flow Feb. 23 at 2:52 PM
$CNSP Energy optimization in cold storage is not marginal. On a ~$3.2M annual bill, a 15–20% peak demand reduction can generate approximately $250K in demand savings. Additional $80K–$120K from load shifting strengthens margins while maintaining a battery reserve for outage events
0 · Reply
_Meowzilla1
_Meowzilla1 Feb. 23 at 12:30 PM
$GOVX $CNSP $CGTL $PLAG \|\
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 8:58 PM
$CNSP https://youtu.be/nCPt9XhiRxk
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 5:33 PM
$CNSP https://youtu.be/VcWJkTGHJVM
0 · Reply
UCF_16
UCF_16 Feb. 21 at 12:48 PM
$CNSP
0 · Reply
UCF_16
UCF_16 Feb. 20 at 1:49 PM
$CNSP
0 · Reply
Wahlaunited
Wahlaunited Feb. 19 at 4:00 PM
$CNSP do we waiting on any news
0 · Reply
UCF_16
UCF_16 Feb. 19 at 3:28 PM
$CNSP
0 · Reply
UCF_16
UCF_16 Feb. 19 at 12:38 AM
$CNSP
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 18 at 8:33 PM
Pressure from Brain Tumors Triggers Self-Destruct Mechanism in Neurons, Study Finds $CNSP https://ibn.fm/Q8tbv #tinygems #stocks
0 · Reply
youbi336
youbi336 Feb. 18 at 8:29 PM
0 · Reply
Sympathy_Trader
Sympathy_Trader Feb. 18 at 3:40 PM
$CNSP $SNSE $SPRB
0 · Reply
iluvetfs
iluvetfs Feb. 18 at 3:17 PM
$SNSE $CNSP next, 620k float.
0 · Reply
Samiam69
Samiam69 Feb. 18 at 2:21 PM
$CNSP Run 🏃 💩💩💩
0 · Reply
dcme010711
dcme010711 Feb. 18 at 2:16 PM
$CNSP I got time let’s see if these guys can produce over next couple of quarters
0 · Reply
UCF_16
UCF_16 Feb. 18 at 2:12 PM
$CNSP
0 · Reply
youbi336
youbi336 Feb. 18 at 1:57 PM
$CNSP be careful thinking this is the bottom. It's only stable because shorts can't hit the bid today til 8pm thanks to the short sale restriction. Tomorrow it'll most likely resume its descent. Stay away from this garbage! You have been warned.
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 17 at 7:32 PM
TinyGemsBreaks – $CNSP Appoints New Executive Leadership Team https://ibn.fm/XXZKJ
0 · Reply